SKAN Group (SKAN) CMD 2025 summary

Digital Integration, Technology, and Industry Positioning

• Integration of new technology into existing customer systems is a key asset, with built-in digital adapters supporting seamless connectivity.

• Pharma industry digital landscapes are less standardized than other sectors, creating opportunities for tailored integration solutions.

• Pharma is still in the early stages of digital transformation compared to other industries.

• Emphasis on digitalization, quality, and customer trust as core cultural values.

• Digital operational technology landscape enables paperless, data-driven manufacturing.

Pre-approved Services, Financial Guidance, and Growth Path

• Targeting CHF 50 million in sales volume and up to 50% EBITDA margin at full capacity for pre-approved services, with ramp-up expected over several years.

• Pre-approved services to accelerate customer time-to-market, with commercialization planned for H2 2026.

• Swissmedic inspection delayed to Q1 next year to ensure readiness, with facility expected to go live in the second half of next year.

• No written customer commitments yet, but significant interest and positive feedback from major pharma and CDMO clients.

• 2025 guidance: mid-teens group net sales growth, with further margin expansion beyond mid-term.

Market Trends, Business Model, and Strategy 2030

• Biopharma market growth driven by chronic diseases, biotechnology advances, and expanding drug applications.

• GLP-1 related order intake was 15.15% last year, with ADCs representing a larger share, especially in production equipment.

• Projects involving ADCs are typically larger due to freeze-drying requirements, increasing demand for isolators.

• Strategy 2030 targets market leadership, expansion into integrated process systems, and increased service and consumables revenue.

• Focus for the next five years is on strengthening core business areas and bringing new facilities online.